NCT03871855: A Study of SHR-1702 Alone or With Camrelizumab in Participants With Advanced Relapsed/Refractory Solid Tumors

NCT03871855
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 1
Drug Category: Therapeutic Antibody, Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 75 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with active or untreated central nervous system (CNS) metastases
https://ClinicalTrials.gov/show/NCT03871855

Comments are closed.

Up ↑